Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 96, Issue , 2015, Pages 207-216

  O'Shea, Joseph P ^a   Faisal, Waleed ^b   Ruane O'Hora, Therese ^a   Devine, Ken J ^a   Kostewicz, Edmund S ^c   O'Driscoll, Caitriona M ^a   Griffin, Brendan T ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Minia University   (Egypt)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Biorelevant dissolution testing; Fenofibrate; Food effect; In vitro in vivo correlations (IVIVC); Lipid based formulations; Physiologically based pharmacokinetic modelling; Pig model; Poorly water soluble drugs (PWSD)

Indexed keywords

EXCIPIENT; FENOFIBRATE; ANTILIPEMIC AGENT; CREMOPHOR; DRUG VEHICLE; MACROGOL DERIVATIVE; OLIVE OIL; POLYSORBATE; POVIDONE; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; EXPERIMENTAL PIG; FOOD; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SOLID STATE; ANIMAL; BIOAVAILABILITY; BIOLOGY; BLOOD; CHEMISTRY; CROSSOVER PROCEDURE; DRUG RELEASE; EXPERT SYSTEM; FOOD DRUG INTERACTION; INTESTINE ABSORPTION; METABOLISM; PIG; RANDOMIZATION; SOLUBILITY;

ANIMALS; BIOLOGICAL AVAILABILITY; COMPUTATIONAL BIOLOGY; CROSS-OVER STUDIES; DRUG COMPOUNDING; DRUG LIBERATION; EXCIPIENTS; EXPERT SYSTEMS; FENOFIBRATE; FOOD-DRUG INTERACTIONS; HYPOLIPIDEMIC AGENTS; INTESTINAL ABSORPTION; MALE; OLIVE OIL; PHARMACEUTICAL VEHICLES; POLYETHYLENE GLYCOLS; POLYSORBATES; POVIDONE; RANDOM ALLOCATION; SOLUBILITY; SURFACE-ACTIVE AGENTS; SUS SCROFA;

EID: 84939192578     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.07.014     Document Type: Article

References (34)

1. L. Di, P.V. Fish, and T. Mano Bridging solubility between drug discovery and development Drug Discovery Today 17 2012 486 495
2. J.M. Butler, and J.B. Dressman The developability classification system: application of biopharmaceutics concepts to formulation development J. Pharm. Sci. 99 2010 4940 4954
3. C.A.S. Bergstrom, R. Holm, S.A. Jorgensen, S.B.E. Andersson, P. Artursson, S. Beato, A. Borde, K. Box, M. Brewster, J. Dressman, K.-I. Feng, G. Halbert, E. Kostewicz, M. McAllister, U. Muenster, J. Thinnes, R. Taylor, and A. Mullertz Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs Eur. J. Pharm. Sci. 57 2014 173 199
4. K.A. Lentz Current methods for predicting human food effect AAPS J. 10 2008 282 288
5. W.N. Charman, C.J.H. Porter, S. Mithani, and J.B. Dressman Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH J. Pharm. Sci. 86 1997 269 282
6. J.M. Custodio, C.-Y. Wu, and L.Z. Benet Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption Adv. Drug Deliv. Rev. 60 2008 717 733
7. R. Sauron, M. Wilkins, V. Jessent, A. Dubois, C. Maillot, and A. Weil Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation Int. J. Clin. Pharmacol. Ther. 44 2006 64 70
8. J.P. Guichard, P. Blouquin, and Y. Qing A new formulation of fenofibrate: suprabioavailable tablets Curr. Med. Res. Opin. 16 2000 134 138
9. H.R. Guzmán, M. Tawa, Z. Zhang, P. Ratanabanangkoon, P. Shaw, C.R. Gardner, H. Chen, J.-P. Moreau, Ö. Almarsson, and J.F. Remenar Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations J. Pharm. Sci. 96 2007 2686 2702
10. H.D. Williams, N.L. Trevaskis, S.A. Charman, R.M. Shanker, W.N. Charman, C.W. Pouton, and C.J.H. Porter Strategies to address low drug solubility in discovery and development Pharmacol. Rev. 65 2013 315 499
11. E.S. Kostewicz, L. Aarons, M. Bergstrand, M.B. Bolger, A. Galetin, O. Hatley, M. Jamei, R. Lloyd, X. Pepin, A. Rostami-Hodjegan, E. Sjogren, C. Tannergren, D.B. Turner, C. Wagner, W. Weitschies, and J. Dressman PBPK models for the prediction of in vivo performance of oral dosage forms Eur. J. Pharm. Sci. 57 2014 300 321
12. Y. Fei, E.S. Kostewicz, M.-T. Sheu, and J.B. Dressman Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach Eur. J. Pharm. Biopharm. 85 2013 1274 1284
13. D. Juenemann, E. Jantratid, C. Wagner, C. Reppas, M. Vertzoni, and J.B. Dressman Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles Eur. J. Pharm. Biopharm. 77 2011 257 264
14. C. Stillhart, G. Imanidis, B.T. Griffin, and M. Kuentz Biopharmaceutical modeling of drug supersaturation during lipid-based formulation digestion considering an absorption sink Pharm. Res. 31 2014 3426 3444
15. J. Junghanns, and R.H. Muller Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 3 2008 295 309
16. C.M. O'Driscoll, and B.T. Griffin Biopharmaceutical challenges associated with drugs with low aqueous solubility - the potential impact of lipid-based formulations Adv. Drug Deliv. Rev. 60 2008 617 624
17. M.L. Christiansen, R. Holm, J. Kristensen, M. Kreilgaard, J. Jacobsen, B. Abrahamsson, and A. Mullertz Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano Emulsifying Drug Delivery System (SNEDDS) Eur. J. Pharm. Sci. 57 2014 164 172
18. H.D. Williams, N.L. Trevaskis, Y.Y. Yeap, M.U. Anby, C.W. Pouton, and C.J.H. Porter Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway Pharm. Res. 30 2013 2976 2992
19. J.R. O'Reilly, O.I. Corrigan, and C.M. O'Driscoll The effect of mixed micellar systems, bile acid/fatty acids, on the solubility and intestinal absorption of clofazimine (B663) in the anesthetized rat Int. J. Pharm. 109 1994 147 154
20. G.A. Kossena, W.N. Charman, C.G. Wilson, B. O'Mahony, B. Lindsay, J.M. Hempenstall, C.L. Davison, P.J. Crowley, and C.J.H. Porter Low dose lipid formulations: effects on gastric emptying and biliary secretion Pharm. Res. 24 2007 2084 2096
21. W. Faisal, T. Ruane-O'Hora, C.M. O'Driscoll, and B.T. Griffin A novel lipid-based solid dispersion for enhancing oral bioavailability of lycopene - in vivo evaluation using a pig model Int. J. Pharm. 453 2013 307 314
22. E. Jantratid, N. Janssen, C. Reppas, and J.B. Dressman Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 2008 1663 1676
23. B.T. Griffin, M. Kuentz, M. Vertzoni, E.S. Kostewicz, Y. Fei, W. Faisal, C. Stillhart, C.M. O'Driscoll, C. Reppas, and J.B. Dressman Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate Eur. J. Pharm. Biopharm. 86 2014 427 437
24. J.W. Moore, and H.H. Flanner Mathematical comparison of dissolution profiles Pharm. Technol. 20 1996 64 74
25. M. Hugo, K. Kunath, and J. Dressman Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate Drug Dev. Ind. Pharm. 39 2013 402 412
26. A. Heinz, K.C. Gordon, C.M. McGoverin, T. Rades, and C.J. Strachan Understanding the solid-state forms of fenofibrate - a spectroscopic and computational study Eur. J. Pharm. Biopharm. 71 2009 100 108
27. A.T. Larsen, A.G. Ohlsson, B. Polentarutti, R.A. Barker, A.R. Phillips, R. Abu-Rmaileh, P.A. Dickinson, B. Abrahamsson, J. Ostergaard, and A. Mullertz Oral bioavailability of cinnarizine in dogs: relation to SNEDDS droplet size, drug solubility and in vitro precipitation Eur. J. Pharm. Sci. 48 2013 339 350
28. M. Vogt, K. Kunath, and J.B. Dressman Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations Eur. J. Pharm. Biopharm. 68 2008 283 288
29. C.L.-N. Vo, C. Park, and B.-J. Lee Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs Eur. J. Pharm. Biopharm. 85 2013 799 813
30. Y. Metsugi, Y. Miyaji, K.-I. Ogawara, K. Higaki, and T. Kimura Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function Pharm. Res. 25 2008 886 895
31. N. Thomas, K. Richter, T.B. Pedersen, R. Holm, A. Mullertz, and T. Rades In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate AAPS J. 16 2014 539 549
32. P.C. Christophersen, M.L. Christiansen, R. Holm, J. Kristensen, J. Jacobsen, B. Abrahamsson, and A. Mullertz Fed and fasted state gastro-intestinal in vitro lipolysis: In vitro in vivo relations of a conventional tablet, a SNEDDS and a solidified SNEDDS Eur. J. Pharm. Sci. 57 2014 232 239
33. C. Stillhart, D. Duerr, and M. Kuentz Toward an improved understanding of the precipitation behavior of weakly basic drugs from oral lipid-based formulations J. Pharm. Sci. 103 2014 1194 1203
34. H.D. Williams, P. Sassene, K. Kleberg, M. Calderone, A. Igonin, E. Jule, J. Vertommen, R. Blundell, H. Benameur, A. Muellertz, C.J.H. Porter, C.W. Pouton, and L. Consortium Toward the establishment of standardized in vitro tests for lipid-based formulations, Part 4: proposing a new lipid formulation performance classification system J. Pharm. Sci. 103 2014 2441 2455